Cargando…
Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis: A qualitative research study
Immunoglobulins are 2nd or 3rd-line treatments in dermatomyositis (DM) or polymyositis (PM) refractory to high-dose corticosteroids and immunosuppressants. Immunoglobulins (2 g/kg/mo) are usually administered intravenously (IVIg) once a month and the patients stay at hospital for a few days. Recentl...
Autores principales: | Chérin, Patrick, Pindi Sala, Taylor, Clerson, Pierre, Dokhan, Annaïk, Fardini, Yann, Duracinsky, Martin, Crave, Jean-Charles, Chassany, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035045/ https://www.ncbi.nlm.nih.gov/pubmed/32049796 http://dx.doi.org/10.1097/MD.0000000000019012 |
Ejemplares similares
-
In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
por: Cozon, Grégoire Jacques Noël, et al.
Publicado: (2018) -
Contribution of Flexig mobile application to assess adherence of patients treated with immunoglobulins in chronic diseases
por: Pindi Sala, Taylor, et al.
Publicado: (2023) -
Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases
por: Cherin, Patrick, et al.
Publicado: (2015) -
Association between killer cell immunoglobulin-like receptor (KIR) polymorphisms and systemic lupus erythematosus (SLE) in populations: A PRISMA-compliant meta-analysis
por: Liang, Hui-ling, et al.
Publicado: (2017) -
Intramuscular administration of autologous total immunoglobulin G induces immunomodulatory effects on T cells in healthy human subjects: An open-labeled prospective single-arm trial
por: Kwon, Byul, et al.
Publicado: (2022)